OR WAIT 15 SECS
The new API for hypothyroidism treatment will replace the hormones that are ineffectively produced by the human thyroid gland.
Bioiberica, a life science company based in Barcelona, Spain, announced the launch of its natural thyroid active pharmaceutical ingredient (API) for the treatment of hypothyroidism, a thyroid hormone deficiency that effects up to 5.3% of the European population.
The new treatment will replace the hormones that are ineffectively produced by the human thyroid gland and targets users that desire a natural origin treatment or who continue to experience symptoms despite using standard synthetic therapy, according to a Nov. 6, 2019 press release.
“There is a clear subset of patients suffering from hypothyroidism with persistent symptoms despite following a standard synthetic thyroid treatment,” said Javier Velasco-Alvarez, R&D director at Bioiberica, in the press release. “Our natural thyroid API, extracted from porcine thyroid glands, targets this unmet need. It contains the hormones-tetraiodothyronine, also known as thyroxine or T4, and triiodothyronine, otherwise known as liothyronine or T3-that are naturally produced by the thyroid gland. Scientific evidence shows that thyroid API is an effective treatment from a natural origin.”
“The development of our new thyroid API is the direct result of collaborative partnership with a key player in the pharmaceutical market,” added Jaume Reguant, healthcare director at Bioiberica, in the press release. “By combining our partner’s knowledge with our leading expertise in the identification and manufacture of specific biomolecules, we have successfully developed a solution that looks to address one of today’s many healthcare challenges.”
The new API was showcased at CPhI Worldwide from Nov. 5–7, 2019 in Frankfurt, Germany.